Neoadjuvant chemotherapy in locally advanced cervical cancer: real-world data from the Cancer Medicines Outcomes Programme (CMOP)

Objective: To report the outcomes of neoadjuvant chemotherapy (NACT) in patients with locally advanced cervical cancer, we conducted a retrospective study of 126 patients. Methods: The electronic chemotherapy prescribing system was used to identify patients from the West of Scotland Cancer Network who received NACT over a 5 year period. Baseline characteristic and treatments details were collected. Association of treatment type and other variables with overall survival (OS) were analysed using Cox proportional hazards model. Results: The median follow up was 30 months. Median age was 44 years (interquartile range 34–54), 86% had squamous pathology and 93% had at least International Federation of Gynaecology & Obstetrics (FIGO) stage II disease at diagnosis. 27%had stage IV disease and 30% had paraaortic nodal involvement. NACT regimens consisted primarily of 3 weekly cisplatin/paclitaxel (63%) or carboplatin/paclitaxel (35%). 86% of patients subsequently received chemoradiotherapy (CCRT), 11% radical radiotherapy alone and the remaining patients progressed or defaulted. Three year OS was 61.8% (95% CI (Confidence Interval) 53.4–71.6). Survival was poorer in patients with neutrophil lymphocyte ratio (NLR) ≥5 (haz-ard ratio 2.8 (95% CI 1.32–5.90)) and in those not receiving CCRT (hazard ratio 2.23 (95% CI 1.01–4.91)). Conclusions: Three year OS was reasonable considering the advanced nature of the cohort and suggests that NACT is an option for women with bulky cervical cancer.

Locally advanced cervical cancer; Neoadjuvant chemotherapy; Chemoradiother-apy; Real-world

[1] Cancer Research UK. Cervical Cancer Statistics. 2018. Available at: https://www.cancerresearchuk.org/health-professional/ca ncer-statistics/statistics-by-cancer-type/cervical-cancer#heading- Three (Accessed: 9 January 2020).

[2] Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. International Journal of Gynaecology and Obstetrics. 2018; 143: 22–36.

[3] Vale CL, Tierney JF, Davidson SE, Drinkwater KJ, Symonds P. Substantial improvement in UK cervical cancer survival with chemoradiotherapy: results of a Royal College of Radiologists’ audit. Clinical Oncology. 2010; 22: 590–601.

[4] Sturdza A, Pötter R, Fokdal LU, Haie-Meder C, Tan LT, Maze-ron R, et al. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEM-BRACE, a multicenter cohort study. Radiotherapy and Oncology. 2016; 120: 428–433.

[5] McCormack M, Kadalayil L, Hackshaw A, Hall-Craggs MA, Symonds RP, Warwick V, et al. A phase II study of weekly neoad-juvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. British Journal of Cancer. 2013; 108: 2464–2469.

[6] Dueňas-González A, Orlando M, Zhou Y, Quinlivan M, Barraclough H. Efficacy in high burden locally advanced cervical cancer with concurrent gemcitabine and cisplatin chemoradiotherapy plus adjuvant gemcitabine and cisplatin: Prognostic and predictive factors and the impact of disease stage on outcomes from a prospective randomized phase III trial. Gynecologic Oncology. 2012; 126: 334–340.

[7] Tang J, Tang Y, Yang J, Huang S. Chemoradiation and adjuvant chemotherapy in advanced cervical adenocarcinoma. Gynecologic Oncology. 2012; 125: 297–302.

[8] Tangjitgamol S, Tharavichitkul E, Tovanabutra C, Rongsriyam K, Asakij T, Paengchit K, et al. A randomized controlled trial comparing concurrent chemoradiation versus concurrent chemoradiation followed by adjuvant chemotherapy in locally advanced cervical cancer patients: ACTLACC trial. Journal of Gynecologic Oncology. 2019; 30: e82.

[9] Shim SH, Kim SN, Chae SH, Kim JE, Lee SJ. Impact of adjuvant hysterectomy on prognosis in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy: a meta-analysis. Journal of Gynecologic Oncology. 2018; 29: e25.

[10] Ferrandina G, Gallotta V, Federico A, Fanfani F, Ercoli A, Chiantera V, et al. Minimally Invasive Approaches in Locally Advanced Cervical Cancer Patients Undergoing Radical Surgery After Chemoradiotherapy: a Propensity Score Analysis. Annals of Surgical Oncology. 2021; 28: 3616–3626.

[11] Mileshkin LR, Moore KN, Barnes E, Gebski V, Narayan K, Bradshaw N, et al. Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: the randomized phase III OUT-BACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274). Journal of Clinical Oncology. 2021; 39: LBA3–LBA3.

[12] West of Scotland Cancer Network. West of Scotland Cancer Network (WoSCAN). 2017. Available at: https://www.woscan.scot. nhs.uk/ (Accessed: 20 January 2020).

[13] Baillie K, Mueller T, Pan J, Laskey J, Bennie M, Crearie C, et al. Use of record linkage to evaluate treatment outcomes and trial eligibility in a real‐world metastatic prostate cancer population in Scotland. Pharmacoepidemiology and Drug Safety. 2020; 29: 653–663.

[14] Information Services Division (ISD) Scotland. ACaDMe. 2018. Available at: http://www.isdscotland.org/Products-and-Service s/ACaDMe/ (Accessed: 2 February 2018).

[15] The R Foundation. The R Project for Statistical Computing. 2017. Available at: https://www.r-project.org/ (Accessed: 2 February 2018).

[16] Guthrie GJK, Charles KA, Roxburgh CSD, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Critical Reviews in Oncology/Hematology. 2013; 88: 218–230.

[17] Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases. 1987; 40: 373–383.

[18] Scottish Government. The Scottish Index of Multiple Deprivation (SIMD). 2012. Available at: http://www.gov.scot/Topics/Statisti cs/SIMD (Accessed: 2 February 2018).

[19] Dastidar GA, Gupta P, Basu B, Basu A, Shah JK, Seal SL. Is neoadjuvant chemotherapy a better option for management of cervical cancer patients of rural India? Indian Journal of Cancer. 2016; 53: 56–59.

[20] Narayan S, Sharma N, Kapoor A, Sharma R, Kumar N, Singhal M, et al. Pros and Cons of Adding of Neoadjuvant Chemotherapy to Standard Concurrent Chemoradiotherapy in Cervical Cancer: a Regional Cancer Center Experience. Journal of Obstetrics and Gynaecology of India. 2016; 66: 385–390.

[21] Ghosh M, Trivedi V, Kaustub K, Kumar B. Feasibility of Neoadjuvant Chemotherapy followed by Concomitant Chemoradiotherapy in Figo Stage IVA Cancer Cervix. International Journal of Contemporary Medical Research. 2018; 5: 2454–7379.

[22] de Azevedo CRAS, Thuler LCS, de Mello MJG, de Oliveira Lima JT, da Fonte ALF, Fontão DFS, et al. Phase II trial of neoadjuvant chemotherapy followed by chemoradiation in locally advanced cervical cancer. Gynecologic Oncology. 2017; 146: 560–565.

[23] Tripathi A, Rawat S. Comparative Study of Neoadjuvant Chemotherapy Followed by Definitive Chemoradiotherapy Versus Definitive Chemoradiotherapy alone in Locally Advanced Carcinoma of Cervix. The Journal of Obstetrics and Gynecology of India. 2019; 69: 546–552.

[24] Pathy S, Benson R, Kumar L, Mathur S, Dadhwal V, Mohanti B. Locally advanced cervical cancer – neoadjuvant chemotherapy followed by concurrent chemoradiation and targeted therapy as maintenance: a phase II study. Journal of Cancer Research and Therapeutics. 2019; 15: 1359–1364.

[25] da Costa SCS, Bonadio RC, Gabrielli FCG, Aranha AS, Dias Genta MLN, Miranda VC, et al. Neoadjuvant Chemotherapy with Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: a Randomized Phase II Trial. Journal of Clinical Oncology. 2019; 37: 3124–3131.

[26] Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al. Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: a Gynecologic Oncology Group Study. Journal of Clinical Oncology. 2009; 27: 4649–4655.

[27] Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, et al. Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: the Open-Label Randomized Phase III Trial JCOG0505. Journal of Clinical Oncology. 2015; 33: 2129–2135.

[28] Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. European Journal of Cancer. 2003; 39: 2470–2486.

[29] Sethi R, Mayadev J, Sethi S, Rash D, Chen L, Brooks R, et al. Patterns of Recurrence in Node-Positive Cervical Cancer Patients Treated with Contemporary Chemoradiation and Dose Escalation: a Multi-Institutional Study. Practical Radiation Oncology. 2019; 9: e180–e186.

[30] Tan L, Pötter R, Sturdza A, Fokdal L, Haie-Meder C, Schmid M, et al. Change in Patterns of Failure after Image-Guided Brachytherapy for Cervical Cancer: Analysis from the RetroEMBRACE Study. International Journal of Radiation Oncology*Biology*Physics. 2019; 104: 895–902.

[31] Cibula D, Pötter R, Planchamp F, Avall-Lundqvist E, Fischerova D, Haie Meder C, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer. International Journal of Gynecological Cancer. 2018; 28: 641–655.

[32] Graham K, Shaikh G, Harrand, RL, Sadozye, AH, Kakumanu S, Reed N. Evaluating the efficacy and survival outcome of 3-weekly neoadjuvant chemotherapy (NACT) followed by radiotherapy in locally advanced cervical cancer. International Journal of Gynecological Cancer. 2012; 22: E681.

[33] Embrace Studies and Embrace Research. Available at: https://www. embracestudy.dk/ (Accessed: 16 October 2020).

[34] Wujanto C, Choo BA, Tan D, Ilancheran A, Ng J, Low JJH, et al. Does external beam radiation boost to pelvic lymph nodes improve outcomes in patients with locally advanced cervical cancer?BMC Cancer. 2019; 19: 385.

[35] Mayadev J, Nunes AT, Li M, Marcovitz M, Lanasa MC, Monk BJ. CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study. International Journal of Gynecologic Cancer. 2020; 30: 1065–1070.

[36] Wu J, Chen M, Liang C, Su W. Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in cervical cancer: a meta-analysis and systematic review. Oncotarget. 2017; 8: 13400–13412.